NCT05196919View on ClinicalTrials.gov

Safety and Efficacy of XT-150 for Facet Joint Osteoarthritis Pain

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

February 24, 2022

Primary Completion Date

September 20, 2023

Study Completion Date

September 20, 2023

Conditions
Facet Joint PainBack PainInflammation
Interventions
BIOLOGICAL

XT-150

XT-150 is a plasmid Deoxyribonucleic acid (DNA) formulated in buffered, D mannose saline solution.

BIOLOGICAL

Placebo

Phosphate-buffered saline for injection

Trial Locations (3)

27103

Center for Clinical Research, Winston-Salem

90403

Source HealthCare, Santa Monica

94558

Neurovations, Napa

All Listed Sponsors
lead

Xalud Therapeutics, Inc.

INDUSTRY